F. Cardenal

1.4k total citations · 1 hit paper
26 papers, 946 citations indexed

About

F. Cardenal is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, F. Cardenal has authored 26 papers receiving a total of 946 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Pulmonary and Respiratory Medicine, 18 papers in Oncology and 4 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in F. Cardenal's work include Lung Cancer Treatments and Mutations (21 papers), Lung Cancer Diagnosis and Treatment (15 papers) and Lung Cancer Research Studies (13 papers). F. Cardenal is often cited by papers focused on Lung Cancer Treatments and Mutations (21 papers), Lung Cancer Diagnosis and Treatment (15 papers) and Lung Cancer Research Studies (13 papers). F. Cardenal collaborates with scholars based in Spain, Germany and United States. F. Cardenal's co-authors include Carlos Camps, Rafael Rosell, Miquel Tarón, José Javier Sánchez, Manuel Dómine, Vicente Alberola, José Miguel Sánchez, Paul H. Gumerlock, Reginald V. Lord and Kathleen D. Danenberg and has published in prestigious journals such as Journal of Clinical Oncology, European Urology and European Journal of Cancer.

In The Last Decade

F. Cardenal

25 papers receiving 916 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer.

2002 551 citations Reginald V. Lord, Jan Brabender et al. PubMed profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
F. Cardenal Spain	8	632	585	416	202	96	26	946
Alberto Cambieri Italy	6	512 0.8×	470 0.8×	336 0.8×	195 1.0×	70 0.7×	6	790
Antonella Flacco Italy	9	482 0.8×	381 0.7×	269 0.6×	179 0.9×	67 0.7×	13	623
Paola Bordi Italy	17	798 1.3×	800 1.4×	413 1.0×	353 1.7×	90 0.9×	51	1.2k
Tejas Patil United States	16	624 1.0×	544 0.9×	228 0.5×	161 0.8×	62 0.6×	67	836
C. Ligorio Italy	6	404 0.6×	426 0.7×	230 0.6×	108 0.5×	87 0.9×	8	614
María Sanchez-Ronco Spain	10	731 1.2×	606 1.0×	507 1.2×	332 1.6×	89 0.9×	15	1.1k
Rebekah A. Burich United States	13	452 0.7×	367 0.6×	262 0.6×	264 1.3×	108 1.1×	22	710
Tahsin M. Khan United States	8	364 0.6×	344 0.6×	275 0.7×	115 0.6×	61 0.6×	23	604
Minaxi Jhawer United States	11	383 0.6×	484 0.8×	305 0.7×	98 0.5×	169 1.8×	14	842
Pil Gyu Hwang South Korea	9	992 1.6×	858 1.5×	341 0.8×	186 0.9×	47 0.5×	11	1.1k

Countries citing papers authored by F. Cardenal

Since Specialization

Citations

This map shows the geographic impact of F. Cardenal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by F. Cardenal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites F. Cardenal more than expected).

Fields of papers citing papers by F. Cardenal

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by F. Cardenal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by F. Cardenal. The network helps show where F. Cardenal may publish in the future.

Co-authorship network of co-authors of F. Cardenal

This figure shows the co-authorship network connecting the top 25 collaborators of F. Cardenal. A scholar is included among the top collaborators of F. Cardenal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with F. Cardenal. F. Cardenal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Faivre‐Finn, Corinne, Linda Ashcroft, W. Appel, et al.. (2017). 142: CONVERT – An international randomised trial of concurrent chemo-radiotherapy (cCTRT) comparing twice-daily (BD) and once-daily (OD) radiotherapy schedules in patients with limited stage small cell lung cancer (LS-SCLC) and good performance status (PS). Lung Cancer. 103. S64–S64. 1 indexed citations

Marinis, Filippo de, R. Rosell, A. Vergnenègre, et al.. (2011). 9016 POSTER DISCUSSION Erlotinib Vs Chemotherapy (CT) in Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients (p) With Epidermal Growth Factor Receptor (EGFR) Activating Mutations – the EURTAC Phase II Randomized Trial Interim Results. European Journal of Cancer. 47. S597–S597. 5 indexed citations

Cardenal, F., Noemı́ Reguart, Teresa Morán, et al.. (2011). 9141 POSTER Phase l/ll Trial of Vorinostat (V) in Combination With Erlotinib (E) in Advanced Non-small Cell Lung Cancer (NSCLC) Patients (pts) With EGFR Mutations After Erlotinib Progression – the TARZO Trial (NCT00503971). European Journal of Cancer. 47. S635–S636. 1 indexed citations

Massutí, Bartomeu, Teresa Morán, R. Porta, et al.. (2009). Multicenter prospective trial of customized erlotinib for advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Final results of the Spanish Lung Cancer Group (SLCG) trial. Journal of Clinical Oncology. 27(15_suppl). 8023–8023. 11 indexed citations

Cardona, Andrés F., Teresa Morán, Noemı́ Reguart, et al.. (2009). Characteristics and outcomes of non-small cell lung cancer (NSCLC) patients (pts) carrying epidermal growth factor receptor (EGFR) mutations who progress after initial erlotinib (E) response. Journal of Clinical Oncology. 27(15_suppl). 8064–8064.

Manegold, C., Johan Vansteenkiste, F. Cardenal, et al.. (2009). Randomized phase II study of three doses of the integrin inhibitor cilengitide versus docetaxel as second-line treatment for patients (pts) with stage IV non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 27(15_suppl). 8014–8014. 5 indexed citations

Karp, Daniel D., Luis Paz‐Ares, Paul Haluska, et al.. (2008). High activity of the anti-IGF-IR antibody CP-751,871 in combination with paclitaxel and carboplatin in squamous NSCLC. Journal of Clinical Oncology. 26(15_suppl). 8015–8015. 38 indexed citations

Garrido, Pilar, R. Rosell, Bartomeu Massutí, et al.. (2008). Predictors of long-term survival in lung cancer patients (p) included in the randomized Spanish Lung Cancer Group 0008 phase II trial using concomitant chemoradiation with docetaxel (D) and carboplatin (Cb) plus induction (I) or consolidation (C) chemotherapy (CT) with docetaxel and gemcitabine (G). Journal of Clinical Oncology. 26(15_suppl). 7574–7574. 1 indexed citations

Porta, R., Cristina Queralt, F. Cardenal, et al.. (2008). Erlotinib customization based on epidermal growth factor receptor (EGFR) mutations in stage IV non-small-cell lung cancer (NSCLC) patients (p). Journal of Clinical Oncology. 26(15_suppl). 8038–8038. 8 indexed citations

10.

Garrido, Pilar, Teresa Morán, F. Cardenal, et al.. (2007). Concomitant chemoradiation plus induction (I) or consolidation (C) chemotherapy (CT) with docetaxel (D) and gemcitabine (G) for unresectable stage III non-small cell lung cancer (NSCLC) patients (p). Results of the randomized SLCG 0008 phase II trial. Journal of Clinical Oncology. 25(18_suppl). 7620–7620. 1 indexed citations

11.

Cobo, M., F. Cardenal, Amelia Insa, et al.. (2007). Skin rash as surrogate marker of efficacy in patients with non-small cell lung cancer treated with erlotinib. Journal of Clinical Oncology. 25(18_suppl). 7602–7602. 6 indexed citations

12.

Cardenal, F., et al.. (2005). Randomized phase II study of sequential versus concurrent chemoradiotherapy (CRT) in poor- risk patients with inoperable stage III non-small cell lung cancer (NSCLC): Interim analysis. Journal of Clinical Oncology. 23(16_suppl). 7255–7255. 4 indexed citations

13.

Garrido, Pilar, António Ramos, Jordi Andreu, et al.. (2005). PD-042 Induction (I) or consolidation (C) chemotherapy withdocetaxel (D) and gemcitabine (G) plus concomitant chemoradiotherapy (CT/TRT) with docetaxel and carboplatin (Cb) for unresectable stage III non-small cell lung cancer (NSCLC) patients (p). Initial report of the randomized phase II trial SLCG 0008. Lung Cancer. 49. S78–S78. 1 indexed citations

14.

Cardenal, F., et al.. (2005). P-706 Randomized phase II study of sequetial versus concurrent chemoradiotherapy (CRT) in poor risk patients with inoperable stage III non-small cell lung cancer (NSCLC): Interim analysis. Lung Cancer. 49. S304–S304. 1 indexed citations

15.

Garcı́a-Martı́n, Miguel, Xavier García del Muro, Ana Fernández Montés, F. Cardenal, & J. R. Germa-Lluch. (2004). Responses in renal cell cancer patients in phase I clinical trials: Drug activity or spontaneous remissions? A systematic review. Journal of Clinical Oncology. 22(14_suppl). 6061–6061. 1 indexed citations

16.

Manegold, C., Jürgen Debus, Giorgio V. Scagliotti, et al.. (2003). 827 A phase II randomized study comparing docetaxel/clsplatin induction therapy followed by thoracic radiotherapy with or without weekly docetaxel in unresectable stage IIIA–IIIB non-small cell lung cancer. European Journal of Cancer Supplements. 1(5). S248–S249. 2 indexed citations

17.

Lord, Reginald V., Jan Brabender, David R. Gandara, et al.. (2002). Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer.. PubMed. 8(7). 2286–91. 551 indexed citations breakdown →

18.

Cardenal, F., Manuel Dómine, Bartomeu Massutí, et al.. (1999). Phase II multi-institutional study of Irinotecan (CPT-11) and Cisplatin (CDDP) on a three-week schedule in patients with advanced non-small cell lung cancer (NSCLC). European Journal of Cancer. 35. S259–S259. 3 indexed citations

19.

Cardenal, F., Á. Artal, M. Lomas, et al.. (1997). 27 Gemcitabine plus cisplatin versus etoposide plus cisplatin in advanced non-small cell lung cancer: A randomized trial by the Spanish lung cancer group. Lung Cancer. 18. 10–10. 3 indexed citations

20.

Muro, Xavier García del, et al.. (1993). Sarcomatoid Renal Cell Carcinoma: A Case of Spontaneous Regression of Metastases. European Urology. 24(2). 300–301. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact